CINCINNATI--(BUSINESS WIRE)--CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, today announced that the first study participant has been dosed in CinDome Pharma’s Phase 2 envision3D study of deudomperidone (CIN-102) in patients with diabetic gastroparesis. Deudomperidone is a Dopamine 2/3 antagonist with prokinetic and antiemetic effects being evaluated for the chronic treatment of patients who currently have no therapeutic options for long term management. Gastroparesis is a syndrome defined by delayed gastric emptying in the absence of any physical obstruction and symptoms include bloating, nausea, vomiting, postprandial fullness, and early satiety.